Skip to main content
. Author manuscript; available in PMC: 2020 Jun 15.
Published in final edited form as: Cell Rep. 2020 May 19;31(7):107651. doi: 10.1016/j.celrep.2020.107651

Figure 3. High-Efficiency Gene Deletion of Primary and Bone-Marrow-Derived Myeloid Cells Using cRNP Complexes.

Figure 3.

(A) Frequency of intracellular Cas9+ bone-marrow-derived macrophage (BMDM) or bone marrow-derived cDC1s (BM-cDC1s) 2 h post-electroporation with 40 pmol Cas9 compared to un-electroporated controls.

(B) Percent of viable BMDMs or BM-cDC1s 4 or 6 days, respectively, after electroporation of 1 × 106 cells at indicated voltages compared to un-electroporated controls.

(C–F) BM-cDC1s, BMDMs, splenic cDC1s, cDC2s, and macrophages were electroporated at 1,900 V in the presence of Itgax or Itgam cRNP complexes. (C) Representative histogram of CD11c expression in BM-cDC1 6 days after electroporation compared to controls electroporated in the presence of Cas9 protein. Percentage of CD11c− BM-cDC1s and CD11b− BMDMs (D) and viable cells (E) 4 or 6 days, respectively, after electroporation. (F) Frequencies of primary splenic CD11c− cDC1, cDC2, and CD11b− macrophages 4 days after electroporation with indicated cRNP complex compared to controls electroporated in the presence of Cas9 protein alone. Data are representative of three independent experiments or three mice per group.